366 related articles for article (PubMed ID: 36375150)
21. Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
Wynia MK; Beaty LE; Bennett TD; Carlson NE; Davis CB; Kwan BM; Mayer DA; Ong TC; Russell S; Steele JD; Stocker HR; Wogu AF; Zane RD; Sokol RJ; Ginde AA
Chest; 2023 May; 163(5):1061-1070. PubMed ID: 36441040
[TBL] [Abstract][Full Text] [Related]
22. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
23. Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar.
Butt AA; Dargham SR; Chemaitelly H; Al Khal A; Tang P; Hasan MR; Coyle PV; Thomas AG; Borham AM; Concepcion EG; Kaleeckal AH; Latif AN; Bertollini R; Abou-Samra AB; Abu-Raddad LJ
JAMA Intern Med; 2022 Feb; 182(2):197-205. PubMed ID: 34935861
[TBL] [Abstract][Full Text] [Related]
24. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
[TBL] [Abstract][Full Text] [Related]
25. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO).
Tuan JJ; Sharma M; Kayani J; Davis MW; McManus D; Topal JE; Ogbuagu O
BMC Infect Dis; 2023 Apr; 23(1):258. PubMed ID: 37101135
[TBL] [Abstract][Full Text] [Related]
27. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
28. Neutralizing Monoclonal Antibodies for Coronavirus Disease 2019 (COVID-19) in Pregnancy: A Case Series.
Richley M; Rao RR; Afshar Y; Mei J; Mok T; Vijayan T; Weinstein S; Pham CU; Madamba J; Shin CS; Suda D; Han CS
Obstet Gynecol; 2022 Mar; 139(3):368-372. PubMed ID: 35115451
[TBL] [Abstract][Full Text] [Related]
29. Bamlanivimab use in mild-to-moderate COVID-19 disease: A matched cohort design.
Destache CJ; Aurit SJ; Schmidt D; Peet Erkes L; Tierney M; Vivekanandan R
Pharmacotherapy; 2021 Sep; 41(9):743-747. PubMed ID: 34328670
[TBL] [Abstract][Full Text] [Related]
30. A Propensity-Matched Cohort Assessing Impact of a Neutralizing Monoclonal Antibody in Mild-to-Moderate Coronavirus Disease 2019.
Abbas M; Farhat N; Hammoud Z; Dickey C; Shuayto A; Chen NW; Hsaiky LM; Sims M; Sengstock D; Schramski J; Shamoon Z
J Intensive Care Med; 2023 Jun; 38(6):511-518. PubMed ID: 36775970
[No Abstract] [Full Text] [Related]
31. Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.
Agrawal P; Damania D; Cseh A; Grab J; Strom L; Frank B; Patel D; Clyatt G
Vaccine; 2023 Aug; 41(35):5195-5200. PubMed ID: 37451874
[TBL] [Abstract][Full Text] [Related]
32. Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA.
Cheng MM; Reyes C; Satram S; Birch H; Gibbons DC; Drysdale M; Bell CF; Suyundikov A; Ding X; Maher MC; Yeh W; Telenti A; Corey L
Infect Dis Ther; 2023 Feb; 12(2):607-621. PubMed ID: 36629998
[TBL] [Abstract][Full Text] [Related]
33. Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients.
Sarrell BA; Bloch K; El Chediak A; Kumm K; Tracy K; Forbes RC; Langone A; Thomas L; Schlendorf K; Trindade AJ; Perri R; Wright P; Concepcion BP
Transpl Infect Dis; 2022 Feb; 24(1):e13759. PubMed ID: 34787345
[TBL] [Abstract][Full Text] [Related]
34. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
Front Immunol; 2021; 12():790469. PubMed ID: 34956222
[TBL] [Abstract][Full Text] [Related]
35. Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
Aggarwal NR; Beaty LE; Bennett TD; Carlson NE; Davis CB; Kwan BM; Mayer DA; Ong TC; Russell S; Steele J; Wogu AF; Wynia MK; Zane RD; Ginde AA
J Infect Dis; 2022 Dec; 226(12):2129-2136. PubMed ID: 35576581
[TBL] [Abstract][Full Text] [Related]
36. Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients.
Douin DJ; Wogu AF; Beaty LE; Carlson NE; Bennett TD; Aggarwal NR; Mayer DA; Ong TC; Russell S; Steele J; Peers JL; Molina KC; Wynia MK; Ginde AA
BMC Infect Dis; 2022 Nov; 22(1):818. PubMed ID: 36344927
[TBL] [Abstract][Full Text] [Related]
37. Single Site Experience of the use of Monoclonal Antibodies for the Treatment of COVID-19 in High-risk Pediatric and Young Adult Patients.
Bahakel H; Murphy C; Frenck RW; Grimley MS; Marsh RA; Paulsen GC; Haslam DB; Phillips CL; Courter J; Spearman P; Schulert G; Danziger-Isakov L
Pediatr Infect Dis J; 2022 Dec; 41(12):985-988. PubMed ID: 36219876
[TBL] [Abstract][Full Text] [Related]
38. Calcitonin Gene-Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder.
Wang K; Fenton BT; Deng Y; Anthony SE; Dao VX; Schindler E; Lipton RB; Guirguis A; Skanderson M; Seng EK; Sico JJ
JAMA Netw Open; 2023 Jul; 6(7):e2326371. PubMed ID: 37523183
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients.
Piccicacco N; Zeitler K; Montero J; Kumar A; Lakshmi S; Kim K; Wein D; Vasey T; Vasey M; Oxner A
Open Forum Infect Dis; 2021 Jul; 8(7):ofab292. PubMed ID: 34258319
[TBL] [Abstract][Full Text] [Related]
40. SARS-CoV-2 neutralizing antibodies for COVID-19: Outcomes for bamlanivimab versus bamlanivimab-etesevimab combination in a racially diverse cohort of patients with significant comorbidities.
Monday LM; Brar I; Alangaden G; Ramesh MS
J Clin Pharm Ther; 2022 Sep; 47(9):1438-1443. PubMed ID: 35633095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
